EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities

Lockwood Taylor, Blythe Adamson

Therapeutic Innovation & Regulatory Science · 2026-07 · 60 (4) · 929-933

DOI: 10.1007/s43441-026-00958-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 26.03.2026. Verfasst von Lockwood Taylor und 1 weiteren Autor:innen. Beteiligte Einrichtung: Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. lockwood.taylor@flatiron.com. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Drug Industry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The new European Union Joint Clinical Assessment (JCA) process, effective January 2025, requires pharmaceutical companies to submit evidence within 100 days of notification. Key challenges include uncertainty about PICO (Population, Intervention, Comparator, Outcomes) parameters prior to PICO notification, limited timeframe for evidence generation, and need to reconcile differences between regulatory versus health technology assessment (HTA) evidence standards. Uncertainties involve predicting PICOs accurately and determining real-world evidence’s (RWE) appropriate role. However, opportunities exist for integrated evidence planning across clinical development, regulatory, and health economics and outcomes research (HEOR) teams, leveraging real-world data to inform or address PICOs as well as support regulatory evidence requirements. Early alignment between key functional teams, combined with proactive RWE use, is essential for generating fit-for-purpose evidence that satisfies the dual scrutiny of regulatory approval and HTA relative effectiveness assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalDrug IndustryEuropean UnionHumansUncertaintyDrug ApprovalEurope

Stichwörter der Autor:innen

EuropeEuropean Medicines Agency (EMA)Evidence generationHealth technology assessment (HTA)Joint clinical assessment (JCA)Real world evidence (RWE)

Autor:innen und Institutionen

  • Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. lockwood.taylor@flatiron.com.
  • Flatiron Health, 233 Spring Street, New York, NY, 10013, USA.

Zitieren

APA

Taylor, L., & Adamson, B. (2026). RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities. Therapeutic Innovation & Regulatory Science, 60(4), 929-933. https://doi.org/10.1007/s43441-026-00958-4

Vancouver

Taylor L, Adamson B. RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities. Therapeutic Innovation & Regulatory Science. 2026;60(4):929-933. doi:10.1007/s43441-026-00958-4

BibTeX
@article{Taylor2026,
  author = {Taylor, Lockwood and Adamson, Blythe},
  title = {RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {4},
  pages = {929--933},
  doi = {10.1007/s43441-026-00958-4}
}
Kostenlos starten →